Theradigm-HBV immunotherapy to activate cytotoxic T cells that will specifically recognize liver cells infected with hepatitis B virus: Began Phase II trials, o

Cytel Corp. (CYTL), San Diego Product: Theradigm-HBV immunotherapy to activate cytotoxic T cells that will specifically recognize liver cells infected with hepatitis B virus (HBV) Indication: Chronic ...